X-linked lymphoproliferative disease type 1 (XLP1) is a rare primary immunodeficiency caused by variants in the SH2D1A gene. This gene encodes the SAP protein, essential for the regulation of T lymphocytes, NK/NKT cells, and the response to Epstein-Barr virus (EBV). Its deficiency leads to an uncontrolled immune response, with a risk of hemophagocytic lymphohistiocytosis, hypogammaglobulinemia, and lymphoma, primarily affecting males due to its X-linked inheritance.
Lymphoproliferative disease (SH2D1A)
The SH2D1A gene (SH2 Domain Containing 1A), located on the X chromosome, provides instructions for making SAP (SLAM-associated protein), an adaptor protein expressed primarily in T cells, NK cells, and NKT cells. SAP participates in SLAM family receptor signaling, which regulates communication between immune cells, cytotoxic lymphocyte activation, NKT cell function, and T and B lymphocyte cooperation.
When pathogenic variants exist in SH2D1A, the SAP protein is deficient, unstable, or absent. As a consequence, the immune system does not properly control certain viral infections, especially Epstein-Barr virus (EBV) infection, and can trigger excessive inflammatory activation. The classic clinical picture includes hemophagocytic lymphohistiocytosis (HLH/LHH) after EBV, hypogammaglobulinemia or dysgammaglobulinemia, and lymphomas, especially B-cell lymphomas. Inheritance is X-linked recessive: hemizygous males are usually affected, while carrier females are generally asymptomatic, although they can transmit the variant. It is an ultra-rare disease, with an estimated incidence close to 1 in 1,000,000 live-born males, with no clearly established ethnic predilection.
Symptoms
Onset usually occurs in infancy or early childhood, often following EBV infection, although some patients present with hypogammaglobulinemia or lymphoma before a recognized infection. HLH manifests with persistent fever, hepatosplenomegaly, cytopenias, liver dysfunction, multi-organ failure, and occasionally neurological involvement. Recurrent infections due to antibody deficiency and B-cell lymphomas, mainly in infancy or adolescence, can also occur. Clinical severity is variable and cannot always be predicted by the specific genetic variant.
Disease management
Management requires follow-up by clinical immunology and prompt action in case of infections or signs of hyperinflammation. EBV-associated HLH is a medical emergency and may require immunosuppression, chemotherapy, and treatment aimed at reducing the viral load or infected B cells. Hypogammaglobulinemia is managed with immunoglobulin replacement therapy and infection prevention. Hematopoietic stem cell transplantation (HSCT) is the only potentially curative treatment for the underlying immunodeficiency, and is considered especially in patients with severe manifestations or before recurrent life-threatening episodes. It is also important to study at-risk family members to identify carriers and affected males early.
Genes analyzed
Bibliography
López-Nevado M, González-Granado LI, Ruiz-García R, et al. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. Front Immunol. 2021 Aug 10;12:671755.
Feteih A, Alkhammash S, Zavalkoff S, et al. A novel pathogenic SH2D1A mutation for X-linked lymphoproliferative syndrome type 1. Clin Immunol. 2020 Oct;219:108569.
Lyu X, Guo Z, Li Y, et al. Identification of a novel nonsense mutation in SH2D1A in a patient with X-linked lymphoproliferative syndrome type 1: a case report. BMC Med Genet. 2018 Apr 12;19(1):60.
